Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RO5520985 |
Trade Name | |
Synonyms | Vanucizumab|Ang-2-VEGF-A CrossMab|RG-7221|RO-5520985 |
Drug Descriptions |
Vanucizumab (RO5520985) is a bispecific human antibody that binds to both Angiopoeitin-2 and VEGF-A, inhibiting tumor angiogenesis and metastasis in xenograft models (PMID: 24097868, PMID: 29217526, PMID: 32162804). |
DrugClasses | |
CAS Registry Number | 1448221-05-3 |
NCIT ID | C118578 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Fluorouracil + Leucovorin + Oxaliplatin + RO5520985 | Fluorouracil Leucovorin Oxaliplatin RO5520985 | 0 | 0 |
Fluorouracil + Leucovorin + RO5520985 | Fluorouracil Leucovorin RO5520985 | 0 | 1 |
RO5520985 | RO5520985 | 0 | 1 |
RO5520985 + Selicrelumab | RO5520985 Selicrelumab | 0 | 1 |